Exploring the Mechanism of Severe Acute Pancreatitis Based on Metagenomics, Metabolomics and Proteomics
1 other identifier
observational
176
1 country
1
Brief Summary
The goal of this observational study is to learn about the biomarkers and mechanisms of severe acute pancreatitis in 30 healthy controls, 30 patients of mild acute pancreatitis, 30 patients of moderately severe acute pancreatitis, and 86 patients of severe acute pancreatitis. The main question it aims to answer are: • The relationship between changes in gut microbiota and clinical prognosis (plasma inflammatory cytokines, incidence and duration of infection in various parts, mortality rate), and the screening and validation of biomarkers that can be used for early prediction of disease severity. • Analyze the relationship between changes in blood composition and clinical prognosis (plasma inflammatory cytokines, incidence and duration of infection in various parts, mortality rate), screen and verify biomarkers that can be used for early prediction of disease severity. Blood and fecal samples from the healthy control group and diagnosed patients will be collected.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 29, 2023
CompletedStudy Start
First participant enrolled
January 21, 2024
CompletedFirst Posted
Study publicly available on registry
January 30, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 9, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 9, 2026
ExpectedJanuary 30, 2024
January 1, 2024
1.1 years
December 29, 2023
January 20, 2024
Conditions
Outcome Measures
Primary Outcomes (4)
Composition of gut microbiota
The gut microbiota plays an important role in protecting the intestinal barrier, regulating metabolism, and participating in immune responses in the human body, and is an important component of the gut ecosystem.
through study completion, an average of 1 year
Composition of gut metabolites
Metabolites can reveal the intrinsic correlation between metabolic products and physiological and pathological changes in the body, thereby achieving recognition of the overall state of the body.
through study completion, an average of 1 year
Composition of metabolites in plasma
Metabolites can reveal the intrinsic correlation between metabolic products and physiological and pathological changes in the body, thereby achieving recognition of the overall state of the body.
through study completion, an average of 1 year
composition of proteins in plasma
Proteins are an important material foundation for life activities and the main executors of life processes such as cell proliferation, differentiation, aging, and death.
through study completion, an average of 1 year
Study Arms (4)
healthy control
mild acute pancreatitis
moderately severe acute pancreatitis
severe acute pancreatitis
Eligibility Criteria
30 healthy controls, 30 patients of mild acute pancreatitis, 30 patients of moderately severe acute pancreatitis and 86 patients of severe acute pancreatitis, a total of 176 cases were included.
You may qualify if:
- Patients group:
- ① Age between 18 and 75 years old;
- ② Within 72 hours of AP onset;
- ③ AP patients who meet the 2012 Atlanta AP Classification and Diagnostic Criteria.
- Healthy control group:
- Age between 18 and 75 years old; ② No history of acute pancreatitis; ③ Routine laboratory tests such as blood routine and fecal routine are normal.
You may not qualify if:
- Used antibiotics, probiotics, and acid suppressants 4 weeks before enrollment;
- Pregnant and lactating women;
- Hypothyroidism, nephrotic syndrome, Cushing's syndrome, AIDS;
- Chronic pancreatitis, pancreatic cancer; ⑤ Severe history of cardiovascular and cerebrovascular diseases and organ dysfunction, such as malignant tumors, heart failure, coronary heart disease, chronic obstructive pulmonary disease, liver and kidney failure; ⑥ Unsigned informed consent form.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 29, 2023
First Posted
January 30, 2024
Study Start
January 21, 2024
Primary Completion
March 9, 2025
Study Completion (Estimated)
December 9, 2026
Last Updated
January 30, 2024
Record last verified: 2024-01